Evidence map›Paper›PMID 40620755›Full record

ArticleChina CDC weekly2025

Drug Resistance of Imported

He Yan, Yan Deng, Siqi Wang, Jianhai Yin, Zhigui Xia, Jianping Cao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

He YanNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Parasite and Vector Biology, World Health Organization Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases; National Institute of Parasitic Diseases (Chinese Center for Tropical Diseases Research), Chinese Center for Disease Control and Prevention, Shanghai, China.
Yan DengYunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research; Yunnan Provincial Center of Malaria Research; Yunnan Institute of Parasitic Diseases Innovative Team of Key Techniques for Vector Borne Disease Control and Prevention; Yunan International Joint Laboratory of Tropical Infectious Diseases, Kunming, Yunnan, China.
Siqi WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Parasite and Vector Biology, World Health Organization Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases; National Institute of Parasitic Diseases (Chinese Center for Tropical Diseases Research), Chinese Center for Disease Control and Prevention, Shanghai, China.
Jianhai YinNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Parasite and Vector Biology, World Health Organization Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases; National Institute of Parasitic Diseases (Chinese Center for Tropical Diseases Research), Chinese Center for Disease Control and Prevention, Shanghai, China.
Zhigui XiaNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Parasite and Vector Biology, World Health Organization Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases; National Institute of Parasitic Diseases (Chinese Center for Tropical Diseases Research), Chinese Center for Disease Control and Prevention, Shanghai, China.
Jianping CaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Parasite and Vector Biology, World Health Organization Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases; National Institute of Parasitic Diseases (Chinese Center for Tropical Diseases Research), Chinese Center for Disease Control and Prevention, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known about this topic?: Artemisinin-based combination therapies (ACTs) remain the first-line treatment for uncomplicated malaria caused by What is added by this report?: The integrated drug efficacy studies (iDES) demonstrated that artesunate (AS) plus dihydroartemisinin-piperaquine (DHA-PPQ) and chloroquine (CQ) remain effective first-line treatments for What are the implications for public health practice?: The iDES and molecular surveillance of antimalarial drug resistance indicated decreasing sensitivity to current first-line treatments. Continued surveillance of antimalarial drug resistance is vital for early warning and appropriate response to the spread of resistant parasites.

Indexed as

antimalarial drug resistancemalariaPlasmodium falciparumPlasmodium vivax

Identifiers

PMID40620755
PMCPMC12228103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.